HKEx Stock Code: 01093English|繁體|简体
Board of Directors
  • CAI Dongchen (Chairman and CEO)
    Mr. Cai, aged 63, Chairman and Chief Executive Officer of the Company, was appointed as an executive director of the Company in 1998. Mr. Cai is also the chairman of the Nomination Committee of the Company and a director of certain subsidiaries of the Group. Mr. Cai holds a MBA degree from Nankai University and has extensive technical and management experience in the pharmaceutical industry. Mr. Cai is a deputy of the 12th National People's Congress of the People's Republic of China (the "PRC").

    Mr. Cai is also a director of True Ally Holdings Limited, Massive Giant Group Limited, Massive Top Limited, March Rise Limited, and the general partner of Beijing Zhongyihe Hezhong Investment Management Centre (Limited Partnership), all of which are substantial shareholders of the Company within the meaning of Part XV of the Securities and Futures Ordinance ("SFO").

  • CHAK Kin Man
    Mr. Chak, aged 51, was appointed as an executive director of the Company in 2005. Mr. Chak is also a director of certain subsidiaries of the Group. Mr. Chak is a certified public accountant of the Hong Kong Institute of Certified Public Accountants and a fellow member of the Association of Chartered Certified Accountants. Mr. Chak holds a bachelor of social sciences degree from The University of Hong Kong and has extensive experience in finance, accounting and investor relation.

  • PAN Weidong
    Mr. Pan, aged 47, was appointed as an executive director of the Company in 2006. Mr. Pan is also a director of certain subsidiaries of the Group. Mr. Pan holds an EMBA degree from Tsinghua University and has extensive experience in finance and accounting.

    Mr. Pan is also a director of Massive Giant Group Limited, Massive Top Limited and March Rise Limited, all of which are substantial shareholders of the Company within the meaning of Part XV of the SFO.

  • WANG Shunlong
    Mr. Wang, aged 52, was appointed as an executive director of the Company in 2008. Mr. Wang holds a doctorate in engineering from Tsinghua University and has spent three years as a visiting researcher at Eindhoven University of Technology in the Netherlands. Mr. Wang has extensive experience in corporate management and investment planning.

    Mr. Wang is also a non-executive director of Consun Pharmaceutical Group Limited (listed on The Stock Exchange of Hong Kong Limited).

  • WANG Huaiyu
    Mr. Wang, aged 53, was appointed as an executive director of the Company in 2010. Mr. Wang is also a director of certain subsidiaries of the Group. Mr. Wang holds a bachelor's degree in microbiology and biochemistry from Hebei University and has extensive technical and management experience in the pharmaceutical industry.

  • LU Jianmin
    Mr. Lu, aged 58, was appointed as an executive director of the Company in 2010. Mr. Lu is also a director of certain subsidiaries of the Group. Mr. Lu has extensive technical and management experience in the pharmaceutical industry.

  • WANG Zhenguo
    Mr. Wang, aged 47, was appointed as an executive director of the Company in 2012. Mr. Wang is also a director of certain subsidiaries of the Group. Mr. Wang holds a bachelor's degree in chemistry from Nankai University and has extensive technical and management experience in the pharmaceutical industry.

  • WANG Jinxu
    Mr. Wang, aged 46, was appointed as an executive director of the Company in 2013. Mr. Wang is also a director of certain subsidiaries of the Group. Mr. Wang holds a bachelor's degree in chemistry from Hebei University, a master's degree in chemical engineering from Hebei University of Technology and a doctorate in chemical engineering from Tianjin University, and has extensive experience in product research and development in the pharmaceutical industry.

  • LU Hua
    Mr. Lu, aged 45, was appointed as an executive director of the Company in 2015. Mr. Lu is also a director of certain subsidiaries of the Group. Mr. Lu holds a bachelor's degree in science (chemistry) from Hebei Normal University, a master's degree in engineering (pharmaceutical manufacturing) from Beijing University of Chemical Technology, an EMBA degree from Tsinghua University and a doctorate in engineering (pharmaceutical manufacturing) from Tianjin University. Mr. Lu has extensive experience in pharmaceutical engineering, production management and technical research.

  • LEE Ka Sze, Carmelo
    Mr. Lee, aged 56, was appointed as a non-executive director in 1996, re-designated as an independent non-executive director in 1998 and further re-designated as a non-executive director in 2004. Mr. Lee is also a member of the Audit Committee and Remuneration Committee and the Company Secretary of the Company. Mr. Lee holds a bachelor of laws degree from The University of Hong Kong. Mr. Lee is a practising solicitor and a partner of Woo, Kwan, Lee & Lo. Mr. Lee is currently a member of the SFC (HKEC Listing) Committee.

    Mr. Lee is also a non-executive director of Hopewell Holdings Limited, Yugang International Limited, Safety Godown Company Limited and Termbray Industries International (Holdings) Limited and an independent non-executive director of KWG Property Holding Limited, Esprit Holdings Limited and China Pacific Insurance (Group) Co., Ltd.. All of the above companies are listed on the Stock Exchange of Hong Kong Limited.

    Mr. Lee was appointed as convenor cum member of the Financial Reporting Review Panel of the Financial Reporting Council for a term of 3 years from 16 July 2016 to 15 July 2019.

  • CHAN Siu Keung, Leonard
    Mr. Chan, aged 59, was appointed as an independent non-executive director of the Company in 2004. Mr. Chan is also the chairman of the Audit Committee and Remuneration Committee and a member of the Nomination Committee of the Company. Mr. Chan is a qualified accountant and a member of the Institute of Chartered Accountants of Ontario. Mr. Chan holds a master of business administration degree from York University, Ontario, Canada and has extensive experience in finance and investment.

  • WANG Bo
    Mr. Wang, aged 56, was appointed as an independent non-executive director of the Company in 2012. Mr. Wang is currently the CEO of Beijing CHNMED Pharmaceutical Technology Development Co., Ltd and managing director of Beijing CHNMED Pharmaceutical Consulting Co., Ltd.. Mr. Wang graduated from Beijing Institute of Iron and Steel and has extensive experience in pharmaceutical policy research and consulting. Mr. Wang is currently the vice-chairman of Chinese Pharmaceutical Enterprises Association and China National Association of Pharmaceutical and Medical Equipment Technical Market.

    Mr. Wang is also an independent director of Hainan Shuangcheng Pharmaceutical Co., Ltd. (listed on Shenzhen Stock Exchange), Guangxi Linzhou Pharmaceutical Co., Ltd. (listed on Shanghai Stock Exchange) and Henan Taloph Pharmaceutical Stock Co., Ltd. (listed on Shanghai Stock Exchange). Mr. Wang was also appointed as independent director of Jiuzhitang Co., Ltd. (listed on Shenzhen Stock Exchange) on 12 May 2016.

    Mr. Wang retired as an independent director of Jiangxu Wuzhong Industrial Co., Ltd. (listed on Shanghai Stock Exchange) on 5 April 2016.

  • LO Yuk Lam
    Mr. Lo, aged 68, was appointed as an independent non-executive director of the Company in 2014. Mr. Lo is currently the President of Saitai Biotechnology Research Institute, Vice-Chairman of Santai Eco Fishery Limited, Chairman of Lo & Associates Limited, Senior Director of Questmark Asia Limited and Senior Advisor of Questmark Capital Management Sdn. Bhd.. Mr. Lo is also involved in public services, currently serving as Chairman of the Advisory Council on Food and Environmental Hygiene of the Food and Health Bureau of the HKSAR, a member of the Advisory Committee of the Vocational Training Council, a general committee member of The Chinese Manufacturers' Association of Hong Kong ("CMA"), Chairman of the Innovation and Technology Committee of the CMA and a consultant of the Chinese Centre for Disease Control and Prevention. Mr. Lo is also an Adjunct Professor of The Chinese University of Hong Kong, a Fellow of The Hong Kong University of Science and Technology and an Honorary Professor of several universities in China. Mr. Lo holds a bachelor's degree in science from the University of Waterloo and an honorary doctorate of philosophy science from York University in the U.S..

    Mr. Lo is also an independent director of Sinovac Biotech Limited (listed on NASDAQ) and an independent non-executive director of Luye Pharma Group Ltd. (listed on The Stock Exchange of Hong Kong Limited).

  • YU Jinming
    Mr. Yu, aged 59, was appointed as an independent non-executive director of the Company in 2014. Mr. Yu is an Academician of Chinese Academy of Engineering, and is currently the Honorary President of Shandong Academy of Medical Sciences and the President of Shandong Cancer Hospital. Mr. Yu holds a bachelor's degree in medicine from Changwei Medical College and a doctorate in radiology from Shandong University.

  • CHEN Chuan
    Mr. Chen, aged 53, was appointed as an independent non-executive director of the Company in 2016. Mr. Chen holds a bachelor's degree in Medicine from Norman Bethune University of Medical Science and a Master's degree in Science from Albert Einstein College of Medicine at Yeshiva University.

    Mr. Chen is also a director of Beijing Dong Fang Ming Kang Medical Equipment Co., Ltd. (quoted on the National Equities Exchange and Quotations System) and an independent director of Jiangsu Wuzhong Industrial Co., Ltd. (listed on Shanghai Stock Exchange).

© Copyright 2017 CSPC Pharmaceutical Group Limited. All Rights Reserved.